results Rockwell quarter continue objectives to last thank webcast. we Good joining and strategic you Heather. pleased this us priorities make to XXXX today morning, we Medical's for call for on year. progress the that am I Thank all outlined and report and third conference time you,
top-line our revenue, by enhancing our and focused all delever reducing efforts our expenses hemodialysis profitability, our on achieving business. keenly concentrates margins, enhancing to are gross driving business Our continuing while
enhancements made strengthen Board we organization experience which review further in and detail. addition, our further updates our and will base.Let's we these elevate to each team our management of Directors, In of believe
of third including of sales of XXXX, which sales $XX.X $XX.X quarter the generated the generated million, million, the of concentrates to-date company. we net were product highest sales During for both
acquisition EBITDA, our completed year, acquisition we elements purchasing to important acquiring from just customer assets market over strategic of in revenue approximately number to acquisition approximately which second a in million accretive adding X,XXX Rockwell, million concentrates to in this is Additionally, facilities our presence annual This immediately and the base. $XX our under adds in Evoqua concentrates Water hemodialysis a Technologies. $X business.Additionally, our new including expands by the
the X/X approximately States, dialysis services now Rockwell including facilities purchasing result, a in and clinics outpatient As United all of hospitals.
In fully when addition, at manufacture currently we fully manufacture we products automated manufacturing process, which a lower have added than a can our cost today. products unlocked,
States.To successfully these to Lastly, bicarbonate by United team into into Rockwell's an these this integration both concentrates the supplier integrate Rockwell leading transition now result business platform. of of Evoqua in liquid and assembled acquiring as a from assets hemodialysis Rockwell we assets, Rockwell, the representatives is led
Evoqua's agreement in was on completed concentrates October customers. of into directly Evoqua's pleased into and entered and Rockwell's Rockwell supply accepting that the to we and assets base and integration report orders the XX-day support business we Evoqua that transition to successfully onboarded the X, customer to integrated system.I began am Evoqua's as Additionally, a customers behalf ensure there disruption with on from patients and served, our no services they and clinics to service transition
our ended important In expenses agreement, reducing transition the thereby associated with milestone services fees the this going addition, forward.
the unleash overall of better to benefit exploring value costs margins. but manufacturing Now reduce customers serve, gross acquisition, to the best not this to we our our patients to only we drive and are how
We quarter, which will with a significant long-term and say on signed have to of minimum continue more third Rockwell's we believe on to purchasing during about and agreements, included that customer number price a increases addition, these impact supply will we future bottom-line. plans calls.In arrangements meaningful commitments have the top
with another products, a realize December restated X.The First, payment products an we extended a for event on right the one-time of for will XXXX. through Rockwell our year, December amended extension, to or will goes such extended which the price XXXX into largest has this customer concentrates this take customer. also entered increase through amended extend our product increased an term. agreement, be our including and could agreement with December purchase the agreement the and Under for after largest term In agreement hemodialysis pricing
not commitment we a and X In amount met, for the be addition, will these will purchase event In the purchasing receive forecasted. to are the forecasts forecasted month Rockwell forecasts least compensated amounts. at
We with agreements we States.In are the customers. existing and work our to new secure with provide addition, long-term customer several other clinics products continue help our to to throughout their largest excited to continue United to product purchase
dry Illinois and is California, first Colorado, Sanderling to terms of Sanderling's and supplier preferred Rockwell focusing Utah. underserved hemodialysis agreement, acid will communities. located patients services of The in-center the on and concentrates and Tennessee, Services, renal in Renal and provider this Under full-service a bicarbonate liquid Nevada, Oklahoma, facilities telemedicine of be rural the throughout
generate This with potential second concentrate over the supply the Rockwell provide hemodialysis concentrates agreement concentrate third concentrates agreement and on purchase outpatient dollars course purchasing millions minimum provider announced in to and In Sanderling preference the to to non-profit mixer quarter our sales Ohio. addition to also accessories, commitment with site. the for in of largest Sanderling contract.A the has Centers of mix Care, net Dialysis and during for we dialysis independent support was Sanderling's acid dry includes will products Rockwell supplying with conveniently acid
a which is is preferred Ohio serving supplier dry Medical of over concentrates agreement footprint and the concentrates to CDC and be X-year hemodialysis and dollar $X of liquid and bicarbonate commitments, this bicarbonate of long-term, Illinois, includes of throughout skilled agreement, Dialyze million supply part generate Rockwell and Rockwell in a Houston We New the acid Dialyze the Direct, supplier we Methodist, and nursing Indiana, As Houston throughout in dialysis and minimum located leading medical distribution center Ohio.Third to its nearly and with XX be acid products signed to setting. Kentucky, of York, Jersey, a purchase greater and Medical facility net includes includes will expand accessories Under will with minimum also this provider New its purchasing purchase hemodialysis Maryland, Direct leading purchasing area. which terms services community related commitments, Medical purchasing multi-million agreement.Lastly supply the agreement, this preferred Pennsylvania. hospitals dry will expect that Rockwell product liquid academic annually the sales X commitments. and facilities
As we stated purchase products, they construct value of provide inherent previously, product such to the we to our these agreements reflect patients. continue that
with the of as Our delivery commercial our United of successful and becoming team of the improve associated our our margins expense is through products. continue global internationally actively gross leading to selling the vision our concentrates.We manufacturing execution of we continue reduction hemodialysis supplier products States pursue to across and
roles During production small another powder facilities Rockwell. redundant our of into and workforce two of quarter that completed of we the dry third eliminated XXXX, reduction some within our consolidated
additional will began this our that our costs delivery route and reduce In path continue manufacturing process. further quarters, the our delivering going consolidated we with to ways finding addition, we value In expenses products. reducing costs unlock a the schedules, manufacturing to looking newly of fully customers.We our be of our to the associated acquired coming optimization down associated are automated program further with aggressively products to
on goal gross have our achieving continue initiative business and in we adding of Considering leaders, adjusted we to margins we at will changes automate look our business. the made, facilities, acquisition hemodialysis other increasing will of on manufacturing great to drive Evoqua's the the manufacturing an our gross concentrates expect strategic strategic is components XXXX.One quarter and north basis operators by Rockwell Additionally, EBITDA including an fourth to that the our higher of industry our to annual with XX% concentrates will we further assets be which of expect thinkers the sales, product margins basis. enhance the process of of of profitable all our our
are have to that pleased done We we announce just that.
of biopharmaceutical Rockwell's in operational than amount First, Rockwell's expertise. led has of we member named Directors. She biotech a of her M&A career, public scaled companies. board development, throughout and number and an XX and of and has as of Joan possessing entrepreneur more a Board significant private experience Joan Lau Dr. companies operator, business scientist, investor to of years October. appointed was Joan CEO, Board founded,
developing malignancies.Previously, Sciences, finance biopharmaceutical he at finance and President of hematological organization. serve valuable Senior improve aspects patients Rockwell join board serve our Prior $XX of to experience company member goal to of Jesse patients public at annual Medical was its and to Senior of as therapeutics of to lives continue was XX grow more as I'm and Neri functions who head achieve private revenue with than excited to a Finance both dialysis customer Vice of all Jesse her the at shareholder Hemavant Jesse of Rockwell increasing Rockwell experience we with blood a oversees of disorders leading be Life as have position Finance Rockwell, to has and value.Also, new of years incredibly of clinical-stage Zyla the joining public Vice pharmaceutical public base products they Sciences, the portfolio to the companies. clinics needs President million. company and Finance Additionally, to company will our a Rockwell's
senior its the including Jesse finance strategic of organization, member of was and reporting, a team, aspects controllership, for audit, planning. As all SEC management responsible
expertise healthcare experience growth.Now with expansion financial turn you within operating While our Rockwell financial to acquisition for to objectives. call launches, growth strategic multiple extensive valuable along as third in Medical provide May our pivotal acquisitions, organizations Jesse to generating, oriented XXXX.Jesse's contemplate approvals, Assertio the our avenues a over leading infrastructure Zyla's be Jesse results advancing ability our commercial while product financing, role to by Jesse's ability regulatory continue and Therapeutics we of of in will with the and enhance will to and quarter. meet finance will businesses strengthening at Zyla, played product various revenue our I